The effect of betamethasone injection on maternal and neonatal outcomes in pregnant women with gestational age 34-37 weeks exposed to preterm labor in Sayyad Shirazi Hospital, Gorgan.

The effect of betamethasone injection on maternal and neonatal outcomes in pregnant women with a gestational age of 34 to 37 weeks

All mothers will be randomly divided into two groups: group A (intervention group or treatment with betamethasone) and group B (control group or normal saline injection). A randomized, double-blind, placebo-controlled clinical trial

All pregnant women with preterm labor symptoms with gestational age of 34 to the end of 36 weeks at Shahid Sayad Shirazi Hospital in Gorgan, double blind clinical trial All medical staff involved in the study will be unaware of the grouping and medication or the placebo receiving by subjects due to coding process and the similarity of the drug and placebo packages.

Inclusion criteria: gestational age between 34-37 weeks, preterm labor symptoms in gestational ages between 34-37 weeks , corticosteroids injection indication before childbirth according to the specialist diagnosis, consent to participate in the study exclusion criteria: intrauterine growth retardation, congenital malformation, Multiple pregnancies, placental abruption, systemic maternal diseases (diabetes, cardiovascular disease and endocrine), receiving two doses of betamethasone before the study, dissatisfaction to participate in the study

Intramuscular injection of betamethasone 12 mg at 2 doses for 24 hours will be given to the intervention group and the same volume of normal saline with the same intervals to the control group.

Respiratory distress syndrome, neonatal death, need for hospitalization in the neonatal intensive care unit, increased FBS and 2Hpp 6 weeks after delivery for mother

We use the block randomization method to randomize subjects into groups that result in equal sample sizes. We use the block size 4. From the following blocks, first select 1 by accident and divide the samples into two groups according to the order and fill the blocks A for intervention and B for placebo B A B A 2) B B A A 1) B A A B 4) A B B A 3) A A B B 6) A B A B 5)

The randomization process will be performed without anyinterference of the people who involved in the study. The drug and the placebo will be prepared in similar packages without the possibility of identification. Based on the classification, The people entered in the study will receive their own coded packages based on the specified classification, and the results will be recorded separately based on the coding on the packages and specifications of the studing groups. At the end of the study, the analyzer will use the sample codes and coding instructions to access the nature of the groups for analysis and conclusion.

Only part of the data, such as information about the main outcome or the like, can be shared.

Start of access period 6 months after printing results

It will be available to researchers working in academic and scientific institutions.

Use of data to complement research on the adverse effects of corticosteroids in pregnant women

Contact the author of the article responsible for the research project data.

Contact the author of the article responsible for the research project data.Specify the type of results requested.